LOGIN  |  REGISTER
Chimerix
Amneal Pharmaceuticals

Perrigo to Attend the Piper Sandler Growth Frontiers Conference

August 27, 2024 | Last Trade: US$24.76 0.32 -1.28

DUBLIN, Aug. 27, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Piper Sandler Growth Frontiers Conference on Tuesday, September 10 at 10:00 AM CDT

Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts.

About Perrigo

Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at www.perrigo.com

Forward-Looking Statements

This press release includes, and the matters discussed in Perrigo's presentation at the Piper Sandler Growth Frontiers Conference will include certain "forward-looking statements" within the meaning of the Private Litigation Securities Reform Act of 1995, as amended. Forward-looking statements relate to future events and involve known and unknown risks, uncertainties and other factors—many of which beyond the Company's control—that may cause the actual results, performance or achievements of the Company to be materially different from its current expectations, assumptions, estimates and projections. Interested persons are urged to consult the Company's filings with the United States Securities and Exchange Commission, available at https://investor.perrigo.com/sec-filings, for a discussion of the Company's business and financial condition and certain material trends, risks, uncertainties and other factors relating thereto, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2023.

Perrigo Investor Contact

Bradley Joseph, Vice President, Global Investor Relations & Corporate Communications,
(269) 686-3373 / This email address is being protected from spambots. You need JavaScript enabled to view it.

Nicholas Gallagher, Senior Manager, Global Investor Relations & Corporate Communications,
(269) 686-3238 / This email address is being protected from spambots. You need JavaScript enabled to view it.

Recursion

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB